Drug-Eluting Stents to Prevent
Coronary Restenosis (Wakefield, MA: Implant Sciences Corp., 2002);
The prospective, randomized, double-blind trial is designed to assess the safety and efficacy of a slow-release dose formulation paclitaxel-eluting TAXUS stent system for the treatment of coronary restenosis. More than 1,000 patients are scheduled to be enrolled at 80 sites, stated Boston Scientific.
The TAXUS program is a series of clinical studies designed to collect data on Boston Scientific's proprietary paclitaxel-eluting stent technology for reducing coronary restenosis, the growth of scar tissue within an artery after angioplasty and stenting.
Potential role of human cytomegalovirus and p53 interaction in
coronary restenosis. Science 1994;265:391-4.
Cardiologists often treat secondary blockages, called
coronary restenosis, by removing the clogging clump of cells.
Multiple predictors of
coronary restenosis after drug-eluting stent implantation in patients with diabetes.
(26), the role of ICAM-1 in the prediction of coronary restenosis was evaluated.
Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era.
[19] G Avades TY: The mechanisms of
coronary restenosis: insights from experimental models.
Two major processes are involved in adverse events following PCI: (a)
coronary restenosis, and (b) progression of disease on the same vessel or in another vessel (2).
The recently completed START trial demonstrated the efficacy of beta radiation for the treatment of
coronary restenosis. Prior to this trial, gamma radiation showed clinical success in preventing restenosis.